林晓雯;张艳华;

• 1:北京大学临床肿瘤学院北京肿瘤医院暨北京市肿瘤防治研究所恶性肿瘤发病机制及转化研究教育部重点实验室

摘要(Abstract)：

目的:探讨铂类抗肿瘤药的临床特点及其研究进展,为临床应用提供参考。方法:通过查阅国内外相关文献,系统地了解铂类抗肿瘤药的临床作用及相关不良反应;并检索近年上市、未获批准及正在进行临床研究的铂类药物,以分析其临床发展趋势。结果与结论:在过去的10年间,药物研发转向注重药物运输靶向介质,这些新药在保留传统铂类化合物的活性的同时,在很大程度上减少了传统铂类药物的不良反应。

关键词(KeyWords)： 铂类;抗肿瘤药;临床评价

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 林晓雯;张艳华;

DOI: 10.14009/j.issn.1672-2124.2011.01.020

参考文献(References)：

• [1]Alberto ME,Lucas MF,Pavelka M,et al.The second-generation anticancer drug Nedaplatin:a theoretical investigation on the hydrolysis mechanism[J].J PhysChem B,2009,113(43):14473.
• [2]Kawai Y,Taniuchi S,Okahara S,et al.Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation[J].Biol Pharm Bull,2005,28(8):1385.
• [3]Kurita H,Yamamoto E,Nozaki S,et al.Multicenter phase 2 study of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma[J].CancerChemother Pharmacol,2010,65(3):503.
• [4]Gong Y,Ren L,Zhou L,et al.PhaseⅡevaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma[J].Cancer Chemother Pharmacol,2009,64(2):327.
• [5]Oshita F,Yamada K,Saito H,et al.PhaseⅡstudy of nedaplatin and irinotecan for elderly patients withadvanced non-small cell lung cancer[J].J Exp TherOncol,2004,4(4):343.
• [6]Kuwahara A,Yamamori M,Nishiguchi K,et al.Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanesepatients with esophageal squamous cell carcinoma[J].IntJ Med Sci,2009,6(6):305.
• [7]Yamashita H,Nakagawa K,Tago M,et al.Radiation therapy combined with cis-diammine-glycolatoplatinum(nedaplatin)and 5-fluorouracil for Japanese stageⅡ-Ⅳesophageal cancer compared with cisplatin plus 5-fluorouracil regimen:a retrospective study[J].DisEsophagus,2006,19(1):15.
• [8]Zheng J,Wang G,Yang GY,et al.Induction chemotherapy with nedaplatin with 5-FU followed byintensity-modulated radiotherapy concurrent with chemo-therapy for locoregionally advanced nasopharyngealcarcinoma[J].Jpn J Clin Oncol,2010,40(5):425.
• [9]石建华.长春瑞宾联合洛铂与联合顺铂治疗晚期非小细胞肺癌的疗效比较[J].现代中西医结合杂志,2008,17(33):5105.
• [10]马文杰,张清媛,赵文辉,等.洛铂联合长春瑞滨治疗32例晚期乳腺癌的临床观察[J].临床肿瘤学杂志,2009,14(9):816.
• [11]Lee WS,Lee GW,Kim HW,et al.A phaseⅡtrial of haptaplatin/5-FU and leucovorin for advanced stomachcancer[J].Cancer Res Treat,2005,37(4):20.
• [12]Lee KH,Hyun MS,Kim HK,et al.Randomized,multicenter,phaseⅢtrial of heptaplatin 1-hour infusionand 5-fluorouracil combination chemotherapy comparingwith cisplatin and 5-fluorouracil combination chem-otherapy in patients with advanced gastric cancer[J].Cancer Res Treat,2009,41(1):12.
• [13]Kelland LR,Abel G,Mckeage MJ,et al.Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyc-lohexylamine platinum(Ⅳ):an orally active platinumdrug[J].Cancer Res,1993,53(11):2581.
• [14]Samimi G,Howell SB.Modulation of the cellularpharmacology of JM118,the major metabolite ofsatraplatin,by copper influx and efflux transporters[J].Cancer Chemother Pharmacol,2006,57(6):781.
• [15]Choy H,Park C,Yao M.Current status and future prospects for satraplatin,an oral platinum analogue[J].Clin Cancer Res,2008,14(6):1633.
• [16]Cmelak AJ,Choy H,Shyr Y,et al.National survey on prophylactic cranial irradiation:differences in practicepatterns between medical and radiation oncologists[J].Int J Radiat Oncol Biol Phys,1999,44(1):157.
• [17]Treat J,Schiller J,Quoix E,et al.ZD0473 treatment inlung cancer:an overview of the clinical trial results[J].Eur J Cancer,2002,38(Suppl 8):S13.
• [18]Campone M,Rademaker-Lakhai JM,Bennouna J,et al.PhaseⅠ and pharmacokinetic trial of AP5346,a DACH-platinum-polymer conjugate,administered weekly for threeout of every 4 weeks to advanced solid tumor patients[J].Cancer Chemother Pharmacol,2007,60(4):523.
• [19]Nowotnik DP,Cvitkovic E.ProLindac(AP5346):areview of the development of an HPMA DACH platinumPolymer Therapeutic[J].Adv Drug Deliv Rev,2009,61(13):1214.
• [20]Stathopoulos GP,Boulikas T,Vougiouka M,et al.Liposomal cisplatin combined with gemcitabine inpretreated advanced pancreatic cancer patients:a phaseⅠ-Ⅱstudy[J].Oncol Rep,2006,15(5):1201.
• [21]Froudarakis ME,Pataka A,Pappas P,et al.Phase 1 trialof lipoplatin and gemcitabine as a second-line chem-otherapy in patients with nonsmall cell lung carcinoma[J].Cancer,2008,113(10):2752.
• [22]Ravaioli A,Papi M,Pasquini E,et al.Lipoplatinmonotherapy:A phaseⅡtrial of second-line treatment ofmetastatic non-small-cell lung cancer[J].J Chemother,2009,21(1):86.
• [23]Mylonakis N,Athanasiou A,Ziras N,et al.Phase Ⅱ study of liposomal cisplatin(Lipoplatin)plus gemcitabineversus cisplatin plus gemcitabine as first line treatment ininoperable(stage IIIB/IV)non-small cell lung cancer[J].Lung Cancer,2010,68(2):240.
• [24]Kosmas C,Angel J,Athanasiou A,et al.9 088 Phase Ⅲ study of Lipoplatin plus Gemcitabine versus Cisplatinplus Gemcitabine in advanced NSCLC;interim analysis[J].Eur J Cancer Suppl,2009,7(2):531.